Interstitial laser coagulation in patients with lower urinary tract symptoms from benign prostatic obstruction:: treatment under sedoanalgesia with pressure-flow evaluation

被引:0
|
作者
Dæhlin, L
Hedlund, H
机构
[1] Univ Bergen, Dept Surg, Div Urol, N-5014 Bergen, Norway
[2] Univ Oslo, Rikshosp, Dept Urol, N-0027 Oslo, Norway
关键词
prostatic hyperplasia; laser; analgesia; pressure-flow;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives To evaluate the effects on lower urinary tract symptoms and pressure-Bow variables after interstitial laser coagulation (ILC) of the prostate using the Indigo(TM) diode laser system (Indigo, Palo Alto, USA). Patients and methods Forty-nine men (median age 68 years, range 52-80) were assessed using symptom scores and voiding variables before and at 3 and 12 months after ILC. A subset of 26 men (median age 68 years, range 63-72) underwent pressure-flow measurements before and at 6 months after ILC. All treatments were performed in the outpatient depart ment using sedoanalgesia. Results The International Prostate Symptom Score decreased from 22 to II at 12 months after ILC. The peak urinary flow (Q(max) )was 8.6 mL/s at baseline and increased to 9.9 mL/s at 12 months. Residual urine volumes were unchanged. The median duration of urinary retention after ILC was 3 days. From pressure-flow recordings. 17 patients were categorized as obstructed and seven as equivocally obstructed before ILC (using the International Continence Society definition). Their Q(max) increased from 7.7 to 9.0 mL/s after 6 months, the detrusor pressure at Q(max) decreased from 68 to 51 cmH(2)O and the Abrams-Griffiths number decreased from 54 to 29 (P < 0.01). Patients with moderate to equivocal obstruction had a greater relief of symptoms than those who were clearly obstructed. Patients with prostate volumes of > 40 mL had a greater decrease in the Abrams-Griffiths number than had patients with smaller prostates. Postoperative perineal pain was reported by 72% of patients; the pain subsided after 1-2 weeks. The re-treatment rate was 15% within the first year. Conclusion Treatment with ILC produced substantial effects on symptoms and moderate to small changes in urodynamic variables. Patients with moderate or equivocal bladder outlet obstruction or large prostates seem to be the best candidates for this treatment. However, treatment was followed by perineal pain for 1-2 weeks in most cases. A long-term follow-up is necessary to determine the role of ILC.
引用
收藏
页码:628 / 636
页数:9
相关论文
共 50 条
  • [31] Relationships between Prostatic Volume and Intravesical Prostatic Protrusion on Transabdominal Ultrasound and Benign Prostatic Obstruction in Patients with Lower Urinary Tract Symptoms
    Wang, Delin
    Huang, Honghong
    Law, Yan Mee
    Foo, Keong Tatt
    ANNALS ACADEMY OF MEDICINE SINGAPORE, 2015, 44 (02) : 60 - 65
  • [32] Transperineal Laser Ablation Treatment for Lower Urinary Tract Symptoms Due to Benign Prostatic Obstruction: Protocol for a Prospective In Vivo Pilot Study
    van Kollenburg, Rob A. A.
    van Riel, Luigi A. M. J. G.
    Bloemen, Paul R.
    Oddens, Jorg R.
    de Reijke, Theo M.
    Beerlage, Harrie P.
    de Bruin, Daniel Martijn
    JMIR RESEARCH PROTOCOLS, 2020, 9 (01):
  • [33] Clinical application of the UroLift® prostatic urethral lift in Spain: Consensus on the treatment of lower urinary tract symptoms associated with urinary flow obstruction and secondary to benign prostatic hyperplasia
    Arjona, M. Fernandez
    Martin, L. Lopez
    Fernandez, L. M. Herranz
    Ojas, B. Sinues
    Bortolo, J. M. Campa
    Cameno, J. Extramiana
    Alcina, E. Lopez
    Martin, I. Povo
    Alba, A. Budia
    Jurado, G. Ordaz
    Garcia, J. M. Osca
    Teruel, M. Peran
    Argente, V. Gimeno
    Beltran, A. Navarro
    Gual, J. Benejam
    Martinez, Y. E. Hernandez
    Enguita, C. Gonzalez
    ACTAS UROLOGICAS ESPANOLAS, 2024, 48 (10): : 732 - 738
  • [34] Botulinum A toxin for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms
    Thomas C.A.
    Chuang Y.-C.
    Giannantoni A.
    Chancellor M.B.
    Current Urology Reports, 2006, 7 (4) : 266 - 271
  • [35] Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia
    Garimella, Pranav S.
    Fink, Howard A.
    MacDonald, Roderick
    Wilt, Timothy J.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2009, (04):
  • [36] Treatment of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction
    Calogero, Aldo E.
    Burgio, Giovanni
    Condorelli, Rosita A.
    Cannarella, Rossella
    La Vignera, Sandro
    AGING MALE, 2018, 21 (04): : 272 - 280
  • [37] SILDENAFIL FOR TREATMENT OF LOWER URINARY TRACT SYMPTOMS SECONDARY TO BENIGN PROSTATIC HYPERPLASIA
    Ragheb, Ahmed M.
    Arafa, Mahmoud M.
    Moussa, Ayman S.
    Massoud, Amr M.
    JOURNAL OF UROLOGY, 2017, 197 (04): : E99 - E99
  • [38] Intraprostatic injections for lower urinary tract symptoms/benign prostatic enlargement treatment
    Lombardo, Riccardo
    Andersson, Karl-Erik
    Tubaro, Andrea
    De Nunzio, Cosimo
    MINERVA UROLOGICA E NEFROLOGICA, 2018, 70 (06) : 570 - 578
  • [39] Tadalafil for the Treatment of Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia
    Rohrbough, C. R.
    Colgan, Bridget
    Gasser, Ollie
    AMERICAN FAMILY PHYSICIAN, 2024, 109 (01) : 83 - 84
  • [40] Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia
    Hwang, Eu Chang
    Gandhi, Shreyas
    Jung, Jae Hung
    Imamura, Mari
    Kim, Myung Ha
    Pang, Ran
    Dahm, Philipp
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2018, (10):